Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TDP2 | O95551 | 1/20 | 0.48 |
| ▸ | PTPRC | P08575 | 3/20 | 0.47 |
| ▸ | S100A4 | P26447 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968311 | 0.88 | ALDH1A1 (0.46) | ALDH1A1TDP2PTPRCS100A4MEN1 | |
| SCHEMBL12236614 | 0.87 | ALDH1A1 (0.51) | ALDH1A1TDP2PTPRCS100A4MEN1 | |
| SCHEMBL3624177 | 0.83 | KCNJ1 (0.60) | ALDH1A1TDP2PTPRCS100A4MEN1 | |
| SCHEMBL6829300 | 0.79 | ALDH1A1 (0.53) | ALDH1A1TDP2PTPRCS100A4MEN1 | |
| SCHEMBL1633977 | 0.78 | ADRA2A (0.46) | ALDH1A1MEN1MAPTKMT2ALMNA | |
| SCHEMBL29525659 | 0.78 | ADRA2A (0.46) | ALDH1A1MEN1MAPTKMT2ALMNA | |
| SCHEMBL1567844 | 0.76 | PTPRC (0.53) | ALDH1A1TDP2PTPRCS100A4MEN1 | |
| SCHEMBL31456586 | 0.75 | PTPRC (0.54) | ALDH1A1TDP2PTPRCS100A4MEN1 | |
| SCHEMBL1527540 | 0.75 | PTPRC (0.54) | ALDH1A1TDP2PTPRCS100A4MEN1 | |
| SCHEMBL2247008 | 0.75 | PNMT (0.46) | ALDH1A1TDP2MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456183-B2 | Guanidino compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456183-B2 | Guanidino compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456183-B2 | Guanidino compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1767525-A1 | Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1767525-A1 | Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7189727-B2 | Guanidino compounds | CHIRON CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189727-B2 | Guanidino compounds | CHIRON CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189727-B2 | Guanidino compounds | CHIRON CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1385823-B1 | GUANIDINO COMPOUNDS AS MELANOCORTIN-4 RECEPTOR (MC4-R) AGONISTS | CHIRON CORP (US) | 2006-12-13 | — | — | EP | disclosed |
| US-6960582-B2 | Guanidino compounds | CHIRON CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050038027-A1 | Novel guanidino compounds | CHIRON CORPORATION | 2005-02-17 | — | — | US | disclosed |
| EP-1385823-A4 | NOVEL GUANIDINO COMPOUNDS | CHIRON CORP (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040248895-A1 | Novel guanidino compounds | CHU DANIEL (US) | 2004-12-09 | — | — | US | disclosed |
| US-6716840-B2 | AGONISTS OF THE MELANOCORTIN-4 RECEPTOR (?MC-4R?); USEFUL TREATING OBESITY AND TYPE 2 DIABETES | CHIRON CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040024211-A1 | Novel guanidino compounds | CHIRON CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1385823-A1 | NOVEL GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20020193595-A1 | Novel guanidino compounds | CHU DANIEL (US) | 2002-12-19 | — | — | US | disclosed |
| WO-2002081443-A1 | NOVEL GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038027-A1 | Novel guanidino compounds | MC4R, MC3R, GCKR | ALDH1A1 4277/4885TDP2 4239/4885PTPRC 4009/4885 |
| US-20040024211-A1 | Novel guanidino compounds | MC4R, MC5R, MC3R | ALDH1A1 3828/4885TDP2 4685/4885PTPRC 2830/4885 |
| US-20020193595-A1 | Novel guanidino compounds | MC4R, MC5R, MC3R | ALDH1A1 3354/4885TDP2 4824/4885PTPRC 2722/4885 |
| US-20040248895-A1 | Novel guanidino compounds | MC4R, MC5R, MC3R | ALDH1A1 2976/4885TDP2 4615/4885PTPRC 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.